ArticleBiotechnology for biofuels and bioproducts2026
Rational structural design for the dual enhancement of catalytic activity and thermal stability of hyaluronidase from Citrobacter portucalensis.
Article in Biotechnology for biofuels and bioproducts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hyaluronidases (HAase) offer a practical route to produce valued low molecular weight hyaluronic acid (LMW-HA) and HA oligosaccharides (o-HA), which are valued across medical, cosmetic, and biomaterials applications due to their enhanced bioactivity and tissue penetration. However, reliable production and scale-up of LMW‑HA and o‑HA remain complicated due to inefficient production method, potential pathogenic hosts, enzymes with limited catalytic proficiency and prone to thermal denaturation. Here, we employed a structure-guided multi-strategy engineering approach to express and optimize a PL8 family hyaluronidase in E. coli, aiming to overcome these industrial bottlenecks. Using the HA tetrasaccharide binding site mapping, residue conservation analysis, and binding energy calculations, we obtained two mutants (T204R and Y97R) with significantly improved catalytic activities of 1.56 × 10⁶ U/mg and 1.43 × 10⁶ U/mg, respectively. Building on the best-performing variant (T204R), stability-focused design yielded T204R/N206H, which extended the inactivation half-life at 45 °C by up to 1.4-fold without loss of activity. This engineered enzyme efficiently generates LMW-HA and o-HA with tunable size distributions under mild conditions. These findings expand the hyaluronidase toolbox with a recombinant PL8 enzyme, enabling controlled enzymatic production of LMW-HA and o-HA for biomedical and personal care applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.